CVAC Research and Charts

CVAC - CureVac NV Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 2024-07-29 (Delayed quote data 2025-05-09)

Last 3.47	Change ⇓ -0.12 (-3.34%)	Volume 619,070
	Open 3.54	High 3.59	Low 3.40

8EMA (Daily) 3.46	40EMA (Daily) 3.25	50EMA (Daily) 3.24	STO (Daily) 55.786	MACD Hist (Daily) 0.025
8EMA (Weekly) 3.267	40EMA (Weekly) 3.36	50EMA (Weekly) 3.54	STO (Weekly) 47.857	MACD Hist (Weekly) 0.094


Company Profile
CureVac NV a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and pre-clinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2, for which the company initiated a Phase 1 clinical trial.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.